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Proinflammatory adipokines (inflammationmarkers) fromvisceral adipose tissuemay initiate the development of insulin resistance
(IR) and endothelial dysfunction (ED). This study’s objective was to investigate the association of five inflammation markers
(CRP and four adipokines: IL-6, TNF𝛼, PAI-1, and adiponectin) with IR (quantitative insulin resistance check index (QUICKI)),
microvascular measures (capillary density and albumin-to-creatinine ratio (ACR)), and endothelial measures (forearm blood flow
(FBF) increases from resting baseline to maximal vasodilation). Analyses were conducted via multiple linear regression. The 295
study participants were between 18 and 45 years of age, without diabetes or hypertension. They included 24% African Americans
and 21% Asians with average body mass index of 25.4 kg/m2. All five inflammation markers were significantly associated with
QUICKI. All but adiponectin were significantly associated with capillary density, but none were associated with ACR. Finally, IL-
6 and PAI-1 were significantly associated with FBF increase. We also identified a potential interaction between obesity and IL-6
among normal-weight and overweight participants: IL-6 appeared to be positively associated with QUICKI and capillary density
(beneficial effect), but the inverse was true among obese individuals.These study findings suggest that inflammation measures may
be potential early markers of cardiovascular risk in young asymptomatic individuals.
1. Introduction
A large body of scientific evidence supports the critical role
of inflammation markers (including adipokines, bioactive
mediators secreted directly from adipocytes, and vascular
cells within adipose tissue) in the development of systemic
inflammation that contributes to vasculopathy and cardiovas-
cular risk within obese individuals [1, 2]. More specifically,
proinflammatory adipokines from visceral adipose tissue
may initiate the development of insulin resistance, microvas-
cular dysfunction, and endothelial dysfunction. Insulin resis-
tance and endothelial dysfunction have both been implicated
in the pathogenesis of hypertension [3–7] and atherosclerosis
[8, 9]. Microvascular dysfunction may affect both peripheral
vascular resistance and insulin-mediated glucose disposal,
thereby contributing to hypertension and insulin resistance,
respectively [10].
The majority of studies examining the association of
adipokines with factors related to increased cardiovascu-
lar risk have been conducted in older and obese subjects
[11]. However, identification of clinically useful predictors
for detecting younger, asymptomatic individuals at risk for
developing microvascular and macrovascular disease might
provide critical opportunities for early intervention and
prevention. Accordingly, the objective of this study was to
investigate whether or not evidence of early pathogenesis
involving inflammation markers is present in healthy young
adult individuals, without diabetes or hypertension. More
specifically, we assessed whether adipokines are associated
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with insulin sensitivity/resistance measured with the quan-
titative insulin sensitivity check index (QUICKI); microvas-
cular baseline (resting) and maximal capillary density; renal
and generalized microvascular function, measured with the
albumin-to-creatinine ratio (ACR); and endothelial dysfunc-
tion measured with the increase in forearm blood flow from
resting baseline to maximal vasodilation (FBF % increase).
2. Materials and Methods
2.1. Study Design and Population. The study was designed to
evaluate the role of inflammation markers in the develop-
ment of insulin resistance, microvascular dysfunction, and
endothelial dysfunction and eventually the progression to
(pre)diabetes and (pre)hypertension. The study protocol was
approved by the Thomas Jefferson University Institutional
Review Board and written informed consent was obtained
from all study subjects. Participants were recruited between
July 2011 and February 2014, in Philadelphia, Pennsylvania,
from (i) the patient population of a large urban academic
family medicine outpatient practice serving 40,000 individ-
uals and (ii) a cohort of 500 young adult African Americans
enrolled in prior investigations of cardiovascular risk. The
main eligibility criteria were (i) age between 18 and 45; (ii)
no clinically diagnosed hypertension, that is, systolic blood
pressure (SBP) < 140mmHg and diastolic blood pressure
(DBP) < 90mmHg; (iii) no clinically diagnosed diabetes. All
study participants have completed a baseline assessment and
are now undergoing a follow-up assessment 2-3 years after
enrollment. In this paper, we used data collected during the
baseline assessments to evaluate the association of inflam-
mation markers with insulin sensitivity/resistance and with
microvascular and endothelial outcomes.
2.2. Data Collection and Study Measures. Information was
collected on participants’ sociodemographics, family history
of diabetes and cardiovascular disease, and anthropometric
measures. Body mass index (BMI) was computed as weight
divided by height squared (kg/m2). Finally, both serum and
urine samples were obtained and analyzed. Blood pressure
was also measured, although it is not the focus of this paper.
2.3. Adipokine (Adiponectin, IL-6, PAI-1, and TNF𝛼) and
CRP Measurement. The adipokine and CRP assays were
performed using commercially available ELISA kits. IL-6
was measured with a kit from R&D Systems (Minneapolis,
MN), with intra-assay coefficient of variation (CV) 4% and
interassay CV 6%. PAI-1 was measured with the Elitest kit
from DiaPharma (West Chester, OH), with intra-assay CV
5% and interassay CV 5%. Kits from R&D Systems were
also used for assays for TNF𝛼 (intra- and interassay CVs
both 5%) and adiponectin (intra- and interassay CVs both <
10%). Finally, hsCRP was also measured with a kit from R&D
Systems (intra- and interassay CVs = 5% and 6%, resp.).
2.4. Glucose and Insulin Measurement. Glucose was ana-
lyzed by the glucose oxidase technique with the Glucostat
analyzer (YSI, Model 27), which was calibrated routinely.
Insulin was assayed using a solid phase radioimmunoassay
(“Coat-A-Count” from Diagnostic Products Corporation,
Los Angeles, CA). The quantitative insulin sensitivity check
index (QUICKI) of insulin sensitivity was computed as the
reciprocal of the sum of the log fasting glucose (mg/dL) and
the log fasting insulin (𝜇U/mL): QUICKI = 1/{log fasting
glucose (mg/dL) + log fasting insulin (𝜇U/mL)} [12]. Higher
QUICKI values indicate greater insulin sensitivity.
2.5. Microvascular Measures (Capillary Density). The cap-
illaroscopy technique was adapted from Serne´ et al. [13],
and details of our protocol have been previously published
[14–16]. In brief, skin nailfold capillaries in the dorsal third
fingerwere visualized at 38.4xmagnification (Olympus stereo
microscope SZX16, Center Valley, PA), linked to a Retiga
2000R monochrome digital camera (QImaging; Surrey, BC)
and aPC computer.Thenailbedwas illuminatedwith a 250W
halogen fiber optic lamp (KL 2500 LCD: Schott-Fostec;
Elmsford, NY), with additional illumination from a 150W
fiberoptic halogen light (B&BMicroscopes, Ltd.;Warrendale,
PA) in darkly pigmented individuals. We photographed (i)
baseline (resting) capillary density, which represents contin-
uously perfused capillaries [13], and (ii) venous occlusion
(maximal capillary density), which represents maximal visu-
alization of all capillaries present, including both perfused
(with active red blood cell motion) and nonperfused (filled
with stagnant, nonmoving red blood cells) capillaries [17].We
utilized a computer-based method for quantifying capillary
density using Image-Pro Premier imaging software (Version
9.1, Media Cybernetics, Inc., Bethesda, MD) [14, 15]. Higher
capillary densities indicate better microvascular structure.
We have found capillaroscopy measurements performed
by trained personnel to be highly reliable, with intraclass
correlation coefficients generally exceeding 0.9 [18].
2.6. Urinary Albumin Excretion. In addition to capillaro-
scopy, we also assessed renal and generalized microvascular
function through urinary albumin excretion [19], specifi-
cally the albumin-to-creatinine ratio (ACR). Urinary albu-
min excretion was determined using a radioimmunoassay
(Diagnostic Products Corporation, Los Angeles, CA) on
timed overnight (approximately 8 hours) urine collections.
Albumin greater than 20𝜇g/min and ACR greater than
30 𝜇g albumin per mg creatinine are considered indicative of
microalbuminuria.
2.7. Endothelial Function. We followed a well standardized,
noninvasive method of postischemic flow mediated vasodi-
lation [20]. This approach assesses the entire forearm vascu-
lature rather than a single large artery. Forearm blood flow
(FBF) was measured at (i) rested baseline (FBFbase) and (ii)
hyperemic induced maximal vasodilation (FBFmax). FBFmax
and the ratio of FBFmax/FBFbase are accepted noninvasive
measures of endothelial function [21]. We analyzed a varia-
tion of the FBF ratio, the percent increase between the FBFbase
and FBFmax, computed as (FBFmax − FBFbase)/ FBFbase ×
100. Greater increases in FBF indicate better endothelial
function.
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2.8. Data Analyses. The objective of these analyses was to
assess the association of inflammation markers (CRP, IL-6,
TNF𝛼, PAI-1, and adiponectin) with
(i) insulin sensitivity/resistance, measured with the
quantitative insulin sensitivity check index
(QUICKI);
(ii) microvascular structure, as reflected in the capillary
density at rest (baseline capillary density) and after
venous occlusion (maximal capillary density);
(iii) renal and generalized microvascular function, as
reflected in the albumin-to-creatinine ratio (ACR);
(iv) endothelial function, measured with the increase in
forearm blood flow from resting baseline to maximal
vasodilation (FBF % increase).
We hypothesized that higher levels of CRP, IL-6, TNF𝛼,
and PAI-1 would have worse profiles with respect to these
outcomes (i.e., low QUICKI, low capillary densities, high
ACR, and small FBF increase), while the reverse would be
true for adiponectin.
We used multiple linear regression to analyze each out-
come separately. All outcomes except for ACR were analyzed
on the original scale, but ACR was analyzed after log-
transformation because of its skewed distribution. For each
outcome, the main model included all five inflammation
measures as predictors (since we aimed to estimate the
independent effect of each marker), as well as age, sex,
race, marital status, employment status, smoking, drinking,
and BMI (classified as normal, overweight, or obese). The
models for the microvascular and endothelial outcomes also
controlled for QUICKI. In additional exploratory analyses,
we evaluated the potential interaction between BMI and
inflammation markers with respect to insulin resistance and
microvascular outcomes. The data analyses were conducted
in SAS 9.4 and Stata 13.1.
3. Results and Discussion
3.1. Results. The study enrolled a total of 312 subjects. After
exclusion of 17 subjects (2 who were found to be ineligible
after enrollment and 15 because of missing data on inflam-
mation measures and/or microvascular and endothelial out-
comes), these analyses were based on 295 subjects.
Table 1 summarizes the characteristics of the study par-
ticipants who were relatively young (18 to 45 years old),
primarily women, and included sizable numbers of both
African Americans and Asian Americans. Most participants
were normotensive, with only about one-fifth having blood
pressure in the prehypertensive range.
Table 2 summarizes the inflammation measures (CRP
and four adipokines), as well as the study outcomes. In
addition, it also summarizes a number of related measures
to more fully characterize the participants, for example,
glucose as a measure of diabetes status, the homeostatic
model assessment index (HOMA) as another measure of
insulin resistance, and forearm vascular resistance as another
measure of endothelial function. Most participants were
Table 1: Summary of study subject characteristics (𝑁 = 295, except
where noted).
Age (years), mean [sd] 27 [7]
Sex, 𝑛 (%)
Female 187 (63)
Male 108 (37)
Race, 𝑛 (%)
Caucasian 160 (54)
African American 72 (24)
Asian American 63 (21)
Marital status, 𝑛 (%)
Not married 242 (82)
Married 53 (18)
Employment status, 𝑛 (%)
Student 181 (61)
Unemployed 22 (8)
Employed 92 (31)
Smoking, 𝑛 (%) 17 (6)
Alcohol, 𝑛 (%) 226 (77)
Weight (kg), mean [sd] 72 [17]
Body mass index (BMI, kg/m2),∗ mean [sd] 25.4 [5.5]
Body mass index status,∗ 𝑛 (%)
Normal weight (BMI < 25) 147 (58)
Overweight (BMI 25–29.9) 69 (27)
Obese (BMI 30+) 37 (15)
Systolic blood pressure (SBP, mmHg), mean [sd] 108 [11]
Diastolic blood pressure (DBP, mmHg), mean
[sd] 66 [8]
Blood pressure status, 𝑛 (%)
Normotensive (SBP < 120 and DBP < 80) 249 (84)
Prehypertensive (SBP 120–139 or DBP 80–89) 46 (16)
SD: standard deviation.
∗
𝑁 = 252 because of missing data.
nondiabetic, although blood glucose appeared to be in the
prediabetic range for about a quarter of them.
Average capillary density was about 37 capillaries per
mm2 at rest and 55 capillaries per mm2 after venous occlu-
sion.Mean ACRwas 2.7mg/g, with only 2 individuals having
values consistent with microalbuminuria, based on either
albumin excretion or ACR (one individual had albumin
1 𝜇g/min but ACR 33.5mg albumin per g creatinine, and
another individual had albumin 23 but ACR 13.3). There was
almost a 9-fold average increase in FBF from baseline to
maximal vasodilation (mean change = 795%).
Table 3 presents the univariable associations (correlation
coefficients) between the five inflammation measures and
the five study outcomes. However, these results may be
confounded by a number of other participant characteristics,
hence the need to adjust for them in multivariable modeling.
3.2. Insulin Sensitivity/Resistance (QUICKI). Table 4 summa-
rizes the results of the multivariable analysis relating the
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Table 2: Summary of inflammation measures (𝑁 = 295), insulin sensitivity/resistance (𝑁 = 293), microvascular measures (𝑁 = 254), urine
albumin excretion (𝑁 = 250), and endothelial measures (𝑁 = 271).
Inflammation measures (𝑁 = 295)
CRP (mg/L), median [iqr] 1.1 [2.0]
IL-6 (pg/mL), median [iqr] 2.0 [1.5]
TNF𝛼 (pg/mL), mean [sd] 9.0 [2.9]
PAI-1 (ng/mL), mean [sd] 47 [26]
Adiponectin (𝜇g/mL), median [iqr] 9.0 [7.7]
Insulin sensitivity/resistance (𝑁 = 293)
Glucose (mg/dL), mean [sd] 95 [8]
Diabetes status, 𝑛 (%)
Normal (glucose < 100) 219 (75)
Prediabetic (glucose 100–125) 74 (25)
HOMA, median [iqr] 1.1 [0.8]
QUICKI, mean [sd] 0.37 [0.03]
Microvascular measures (𝑁 = 254)
Capillary density: at rest (# capillaries per mm2), mean [sd] 37 [8]
Capillary density: venous occlusion (# capillaries per mm2), mean [sd] 55 [12]
Urine albumin excretion (𝑁 = 250)
Albumin (𝜇g/mL), median [iqr] 1.9 [2.6]
Albumin (𝜇g/min), median [iqr] 1.4 [1.9]
Albumin-to-creatinine ratio (ACR, mg/g), median [iqr] 2.8 [3.8]
Endothelial measures (𝑁 = 271)
FBF postischemic, mean [sd] 27 [9]
FBF ratio (postischemic to baseline), mean [sd] 9 [3]
FBF increase from baseline to postischemic (%), mean [sd] 795 [330]
FVR postischemic, median [iqr] 2.9 [1.4]
FVR ratio (baseline to postischemic), median [iqr] 0.12 [0.07]
FVR decrease from baseline to postischemic (%), mean [sd] 87 [6]
iqr: interquartile range. sd: standard deviation.
FBF: forearm blood flow. FVR: forearm vascular resistance.
Table 3: Correlations (𝑝 values) between inflammation measures and insulin sensitivity, microvascular structure and function, and
endothelial function.
QUICKI Baseline capillary density Maximal capillary density ACR∗ FBF % increase
CRP∗ −0.28 (0.001) −0.12 (0.048) −0.13 (0.038) −0.02 (0.802) −0.07 (0.256)
IL-6∗ −0.11 (0.051) 0.14 (0.027) 0.16 (0.010) 0.05 (0.471) −0.26 (0.001)
TNF𝛼 −0.02 (0.752) −0.17 (0.008) −0.20 (0.002) −0.05 (0.400) 0.07 (0.285)
PAI-1 −0.29 (0.001) −0.09 (0.175) −0.15 (0.014) 0.01 (0.932) −0.03 (0.645)
Adiponectin∗ 0.43 (0.001) 0.10 (0.125) 0.00 (0.967) −0.02 (0.718) 0.07 (0.280)
∗These measures were log transformed because of skewness.
five inflammation measures to insulin sensitivity/resistance.
The results are expressed as the average mean difference in
QUICKI associated with a difference of about 1 standard
deviation in each marker’s levels. For example, for each
additional 8𝜇g/mL in adiponectin, QUICKI was estimated
to be higher by about 0.009 on average. All five inflammation
markers were significant predictors of QUICKI. Their effects
were in the hypothesized directions, with the exception
of IL-6 (higher IL-6 levels were associated with higher
QUICKI values, i.e., better insulin sensitivity). Furthermore,
the estimated effects were not trivial. Given that the standard
deviation of QUICKI was 0.03 (Table 2), the magnitude of
these associations was between a quarter and a third of a
standard deviation of the outcome.
3.3. Microvascular Structure (Capillary Density) and Function
(ACR). Table 5 summarizes the results of the multivariable
analysis relating the five inflammation measures to the
baseline capillary density (at rest), the maximal capillary
density (after venous occlusion), and the ACR. CRP showed
consistent associations with both capillary density measures
(𝑝 = 0.009 and 0.004, resp.), while TNF𝛼 and PAI-1
were significantly associated only with the maximal capillary
density (𝑝 = 0.020 and 0.009, resp.). IL-6 was also a
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Table 4: Association of the inflammation measures with insulin
sensitivity (QUICKI).
Inflammation measure QUICKI
Increment D (95% CI) 𝑝
CRP (mg/L) 2 −0.007 (−0.010, −0.004) 0.001
IL-6 (pg/mL) 2 0.007 (0.002, 0.011) 0.003
TNF𝛼 (pg/mL) 3 −0.004 (−0.008, −0.001) 0.042
PAI-1 (ng/mL) 25 −0.006 (−0.009, −0.003) 0.001
Adiponectin (𝜇g/mL) 8 0.009 (0.004, 0.014) 0.001
𝐷: estimated mean difference for QUICKI, corresponding to the increment
shown (∼1 standard deviation) for each inflammation measure. CI: confi-
dence interval.
The model controlled for age, sex, race, marital status, employment status,
smoking, drinking, and BMI.
significant predictor of both capillary density measures (𝑝 =
0.001 and 0.083, resp.). However, this association was not
monotonic. Compared to low levels of IL-6, intermediate lev-
els were associatedwith better baseline andmaximal densities
(on average, by 4.6 capillaries per mm2 and 3.9 capillaries
per mm2, resp.). The magnitudes of these differences were
about a third of the standard deviations of the two capillary
density measures (8 and 12, resp., Table 2). In contrast, high
levels of IL-6 were not associated with significantly different
capillary densities than low levels of IL-6. None of the five
inflammation measures were significantly associated with
ACR.
3.4. Endothelial Function (FBF % Increase from Baseline to
MaximalVasodilation). Table 6 summarizes the results of the
multivariable analysis relating the five inflammation mea-
sures to endothelial function. Neither CRP nor TNF𝛼 were
significantly associated with endothelial function (𝑝 = 0.721
and 0.112, resp.), but higher levels of IL-6 were monotonically
associated with worse levels of FBF change from baseline to
maximum vasodilation: for each additional 2 pg/mL of IL-
6, there was a smaller change in FBF by 84% (𝑝 = 0.005).
In contrast, PAI-1 and adiponectin showed associations with
endothelial function in unexpected directions. Higher levels
of PAI-1 were associated with stronger FBF increases (i.e.,
beneficial effect, 𝑝 = 0.024), while the reverse was true for
adiponectin (i.e., harmful effect, 𝑝 = 0.088).
3.5. Potential Moderating Effect of BMI on the Role of the
Adipokines. In the main analyses, in the entire study popula-
tion, IL-6 had an unexpected direction in its association with
QUICKI (beneficial effect) and a nonmonotonic (inverse-
U-shaped) association with capillary density (as described
above, Tables 4 and 5). These patterns were apparently
induced by an interaction between IL-6 and BMI (Figure 1).
Among individuals of normal weight, higher IL-6 levels
appeared to be associated with better outcomes (higher
QUICKI and capillary densities) than lower IL-6 levels.
In contrast, the reverse was true among obese individuals.
However, these qualitative interactions were not statistically
significant (adjusted𝑝 = 0.693 forQUICKI, 0.195 for baseline
capillary density, and 0.835 for maximal capillary density),
as the study sample was too small for such assessment.
The unexpected direction of the associations of PAI-1 and
adiponectin with endothelial function also appeared to be
partly due to similar but nonsignificant interactionswith BMI
(results not shown).
3.6. Other Predictors of Insulin Resistance and Microvascular
and Endothelial Outcomes. Regarding additional potential
predictors of cardiovascular risk, African Americans had
significantly lower QUICKI than Caucasians (adjusted 𝑝 =
0.001), indicating greater insulin resistance. African Ameri-
cans also had indications of lowermicrovascular density (𝑝 =
0.170 for baseline density and 0.046 for maximal density).
Body mass index (BMI) had a significant independent asso-
ciation with both QUICKI (𝑝 = 0.001) and FBF % increase
(𝑝 = 0.010), with particularly pronounced effects for obese
individuals. In secondary analyses, we also found that self-
reported family history ofmyocardial infarction or strokewas
associated with worse endothelial function (𝑝 = 0.013 for
FBF % increase).
4. Discussion
The majority of studies examining the association of
adipokines with cardiovascular risk factors have been con-
ducted in older and obese subjects [11]. Based on a Medline
search of previously published literature, to our knowledge,
this is the first study examining the association of adipokines
with insulin resistance and microvascular and endothelial
dysfunction in healthy young adults. Young adults without
diabetes or hypertension were specifically enrolled in order
to study these associations in healthy individuals, prior to
clinical evidence of target organ damage. We verified the lack
of target organ damage with our urine albumin excretion
measurements (with only 2 of the 295 participants having had
mildly elevated values).
One strength of our study is its diverse population, with
sizable numbers of bothAfricanAmericans andAsians. Para-
doxically, African Americans are not well-studied regard-
ing adipokines and microvascular/endothelial dysfunction,
although these markers are risk factors for cardiovascular
disease, which occurs more commonly and is associated
with greater morbidity/mortality in African Americans com-
pared to Caucasians [22]. Another strength of our study
is that our analyses controlled for a number of participant
characteristics (including BMI), in order to determine the
independent associations between the inflammationmarkers
and the outcomes of interest.
We found that higher levels of CRP, as well as of PAI-1
and TNF𝛼, were independently associated with both insulin
resistance and microvascular dysfunction (lower capillary
density). Our CRP results are consistent with a multitude
of studies showing a linear relationship between CRP and
cardiovascular risk [2], including the risk of progression to
diabetes mellitus [23]. CRP has also been previously corre-
latedwith both insulin resistance and endothelial dysfunction
in healthy adults [24], but the average age of subjects in that
study was 59 years, in contrast to 27 years in our study.
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Table 5: Association of the inflammation measures with microvascular structure (capillary densities) and function (ACR).
Inflammation measure Baseline capillary density: at rest Maximal capillary density: aftervenous occlusion ACR
(# capillaries per mm2) (# capillaries per mm2) (mg albumin per g creatinine)
Increment D (95% CI) p D (95% CI) p R (95% CI) p
CRP (mg/L) 2 −1.7 (−2.9, −0.4) 0.009 −2.7 (−4.6, −0.9) 0.004 1.13 (0.96, 1.33) 0.158
IL-6 (pg/mL) 2 0.001 0.083 0.99 (0.81, 1.21) 0.918
<1.5 Ref. Ref.
1.5–3.4 4.6 (2.2, 6.9) 0.001 3.9 (0.5, 7.4) 0.026
3.5+ 1.2 (−2.7, 5.0) 0.554 2.4 (−3.2, 8.0) 0.397
TNF𝛼 (pg/mL) 3 −1.2 (−2.5, 0.2) 0.089 −2.4 (−4.4, −0.4) 0.020 1.04 (0.87, 1.24) 0.688
PAI-1 (ng/mL) 25 −0.4 (−1.5, 0.7) 0.515 −2.2 (−3.8, −0.5) 0.009 1.12 (0.97, 1.29) 0.137
Adiponectin (𝜇g/mL) 8 0.9 (−0.8, 2.7) 0.300 −0.7 (−3.3, 1.9) 0.619 0.93 (0.74, 1.17) 0.523
ACR: albumin-to-creatinine ratio.
𝐷: estimated mean difference for the outcome, corresponding to the increment shown (∼1 standard deviation) for each inflammation measure. 𝑅: estimated
geometric mean ratio for the outcome (analyzed after log-transformation because of skewness), corresponding to the increment shown (∼1 standard deviation)
for each inflammation measure. CI: confidence interval.
The models controlled for age, sex, race, marital status, employment status, smoking, drinking, BMI, and QUICKI.
Table 6: Association of the inflammationmeasures with endothelial
function (FBF % increase from baseline to maximum vasodilation).
Inflammation measure FBF % increase: baseline tomaximum vasodilation
Increment 𝐷 (95% CI) 𝑝
CRP (mg/L) 2 9 (−39, 56) 0.721
IL-6 (pg/mL) 2 −84 (−143, −26) 0.005
TNF𝛼 (pg/mL) 3 42 (−10, 95) 0.112
PAI-1 (ng/mL) 25 49 (6, 91) 0.024
Adiponectin (𝜇g/mL) 8 −62 (−133, 9) 0.088
FBF: forearm blood flow.
𝐷: estimated mean difference for % FBF increase, corresponding to the
increment shown (∼1 standard deviation) for each inflammation measure.
CI: confidence interval.
The model controlled for age, sex, race, marital status, employment status,
smoking, drinking, BMI, and QUICKI.
PAI-1 is a key regulatory coagulation protein. Accordingly,
elevated levels of PAI-1 in inflammatory and obese states are
thought to contribute to the elevated cardiovascular risk via
development of a prothrombotic state [2]. For TNF𝛼, our
findings are consistent with previous animal studies showing
improved insulin sensitivity following deletion of TNF𝛼 or
TNF𝛼 receptors [25] and human studies demonstrating cor-
relation of TNF𝛼 with insulin resistance in the Framingham
Offspring study [26]. We also found that higher levels of
adiponectin were associated with higher insulin sensitivity.
Adiponectin is the most highly expressed protein in adipose
tissue [27] but is antiatherogenic in action, in contrast to the
other adipokines [2]. Thus, our finding is consistent with the
hypothesized cardioprotective effect of adiponectin.
Overall, IL-6 appeared to have an unexpected (protective
and/or nonmonotonic) association with insulin sensitivity
and capillary density. However, this overall finding may
reflect an interaction of IL-6 with obesity; that is, higher
levels of IL-6 may be associated with higher insulin sensi-
tivity and capillary density among normal-weight individuals
(beneficial effect), but an inverse (harmful) relationship may
exist with these outcomes among obese individuals. In prior
studies, conflicting results have been reported with regard
to IL-6 in insulin resistance [28]. In vitro, IL-6 directly
induces insulin resistance in adipocytes, while, in skeletal
muscle cells, IL-6 appears to have an insulin-sensitizing effect
[29]. Yet, circulating IL-6 levels are consistently elevated
in obese and insulin-resistant individuals [28]. Therefore,
it has been theorized that persistent IL-6 increases found
in chronic inflammation and obesity may have detrimental
effects, while transient increases in IL-6 found in lean, healthy
individuals may play a physiological role in normal glucose
homeostasis [28]. Supportive of this theory is the finding
of beneficial effects of IL-6 in contracting muscles during
exercise. Specifically in this setting, IL-6 has biological roles
including induction of lipolysis and suppression of TNF
production [30], in contrast to the negative effects of IL-6
in obesity and adipose tissue. Clinically, a large study of 620
women over the age of 65 overall showed that women in the
highest IL-6 tertile were at higher risk of all-cause mortality
[31]. However, the relative risk associated with high IL-6 was
not significant among those without cardiovascular disease—
healthy older women.
Our findings of a progressive change from a beneficial
effect of IL-6 on both insulin sensitivity and capillary density
in normal-weight individuals, to a negative effect on these
outcomes in obese individuals, are intriguing and consistent
with these previous reports. However, these findings are
speculative, as our study was too small to formally establish
the existence of an interaction between IL-6 and obesity.
Furthermore, a harmful IL-6 effect on endothelial measures
was uniformly present among all BMI subgroups.
None of the five inflammation measures were signif-
icantly associated with ACR in our study, although CRP
[32] and PAI-1 [33] have previously been associated with
microalbuminuria. As in our study, participants in those
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Figure 1: Association of IL-6 with insulin sensitivity/resistance (a) and microvascular structure (b), among normal-weight, overweight, and
obese subjects.
studies were normotensive, but they had somewhat higher
blood pressures, underscoring the known relationship of
blood pressure and age with microalbuminuria, a known
cardiovascular risk factor [34]. However, subjects in these
prior studies (average ages 46 and 58) were older than
those in our study (average age 27). It is possible that
the effect of inflammation on microalbuminuria requires a
somewhat longer period of time to appear than that on other
cardiovascular risk measures evaluated in this study: insulin
resistance and microvascular and endothelial dysfunction.
5. Conclusions
Adipokine and CRP levels are significantly associated with
insulin resistance and microvascular and endothelial dys-
function in young adults without diabetes or hypertension.
8 Mediators of Inflammation
Our study findings suggest that inflammation measures
may be potential early markers of cardiovascular risk in
asymptomatic individuals. Longitudinal studies of inflam-
mation measures as early predictors of later development of
cardiovascular risk factors (diabetes and hypertension) and
cardiovascular events are needed.
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